American Association for Cancer Research
Browse
15357163mct081152-sup-mct-08-1152--suppl_fig_2.pdf (975.33 kB)

Supplementary Fig. S2 from Silibinin inhibits translation initiation: implications for anticancer therapy

Download (975.33 kB)
journal contribution
posted on 2023-03-31, 23:26 authored by Chen-Ju Lin, Rami Sukarieh, Jerry Pelletier
Supplementary Fig. S2 from Silibinin inhibits translation initiation: implications for anticancer therapy

History

ARTICLE ABSTRACT

Silibinin is a nontoxic flavonoid reported to have anticancer properties. In this study, we show that silibinin exhibits antiproliferative activity on MCF-7 breast cancer cells. Exposure to silibinin leads to a concentration-dependent decrease in global protein synthesis associated with reduced levels of eukaryotic initiation factor 4F complex. Moreover, polysome profile analysis of silibinin-treated cells shows a decrease in polysome content and translation of cyclin D1 mRNA. Silibinin exerts its effects on translation initiation by inhibiting the mammalian target of rapamycin signaling pathway by acting upstream of TSC2. Our results show that silibinin blocks mammalian target of rapamycin signaling with a concomitant reduction in translation initiation, thus providing a possible molecular mechanism of how silibinin can inhibit growth of transformed cells. [Mol Cancer Ther 2009;8(6):1606–12]

Usage metrics

    Molecular Cancer Therapeutics

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC